Optimizing Cardiac Delivery of Modified mRNA

Molecular Therapy

Volumn 25, Issue 6, 2017, Pages 1306-1315

  Sultana, Nishat ^a   Magadum, Ajit ^a   Hadas, Yoav ^a   Kondrat, Jason ^a   Singh, Neha ^a   Youssef, Elias ^a   Calderon, Damelys ^a   Chepurko, Elena ^a   Dubois, Nicole ^a   Hajjar, Roger J ^a   Zangi, Lior ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

delivery; heart; modified mRNA

Indexed keywords

CALCIUM PHOSPHATE; CITRIC ACID; LIPOFECTAMINE; MESSENGER RNA; POLYETHYLENEIMINE; PSEUDOURIDINE; REAGENT; SUCROSE; BIOLOGICAL MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC MUSCLE CELL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; GENE TARGETING; GENETIC TRANSFECTION; HEART INJURY; HEART TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEWBORN; NONHUMAN; PROTEIN MODIFICATION; RAT; RNA TRANSLATION; SOMATIC GENE THERAPY; ANIMAL; CARDIAC MUSCLE; CELL CULTURE; CHEMISTRY; FEMALE; GENE EXPRESSION; GENE TRANSFER; GENETICS; HUMAN; MALE; METABOLISM; MOLECULAR IMAGING; PROTEIN SYNTHESIS; REPORTER GENE;

ANIMALS; BIOMARKERS; CELLS, CULTURED; FEMALE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENES, REPORTER; HUMANS; MALE; MICE; MOLECULAR IMAGING; MYOCARDIUM; MYOCYTES, CARDIAC; PROTEIN BIOSYNTHESIS; RATS; RNA, MESSENGER; TRANSFECTION;

EID: 85017339017     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1016/j.ymthe.2017.03.016     Document Type: Article

References (38)

1. 1 del Monte, F., Hajjar, R.J., Efficient viral gene transfer to rodent hearts in vivo. Methods Mol. Biol. 219 (2003), 179–193.
2. 2 Del Monte, F., Ishikawa, K., Hajjar, R.J., Gene Transfer to Rodent Hearts In Vivo. Methods Mol. Biol. 1521 (2017), 195–204.
3. 3 Ylä-Herttuala, S., Bridges, C., Katz, M.G., Korpisalo, P., Angiogenic gene therapy in cardiovascular diseases: dream or vision?. Eur. Heart J., 2017, ehw547.
4. 4 Andrieu-Soler, C., Bejjani, R.A., de Bizemont, T., Normand, N., BenEzra, D., Behar-Cohen, F., Ocular gene therapy: a review of nonviral strategies. Mol. Vis. 12 (2006), 1334–1347.
5. 5 Chaanine, A.H., Kalman, J., Hajjar, R.J., Cardiac gene therapy. Semin. Thorac. Cardiovasc. Surg. 22 (2010), 127–139.
6. 6 Felgner, P.L., Nonviral strategies for gene therapy. Sci. Am. 276 (1997), 102–106.
7. 7 Pahle, J., Walther, W., Vectors and strategies for nonviral cancer gene therapy. Expert Opin. Biol. Ther. 16 (2016), 443–461.
8. 8 Michelfelder, S., Lee, M.K., deLima-Hahn, E., Wilmes, T., Kaul, F., Müller, O., Kleinschmidt, J.A., Trepel, M., Vectors selected from adeno-associated viral display peptide libraries for leukemia cell-targeted cytotoxic gene therapy. Exp. Hematol. 35 (2007), 1766–1776.
9. 9 Jirikowski, G.F., Sanna, P.P., Maciejewski-Lenoir, D., Bloom, F.E., Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA. Science 255 (1992), 996–998.
10. 10 Wolff, J.A., Malone, R.W., Williams, P., Chong, W., Acsadi, G., Jani, A., Felgner, P.L., Direct gene transfer into mouse muscle in vivo. Science 247 (1990), 1465–1468.
11. 11 McIvor, R.S., Therapeutic delivery of mRNA: the medium is the message. Mol. Ther. 19 (2011), 822–823.
12. 12 Zangi, L., Lui, K.O., von Gise, A., Ma, Q., Ebina, W., Ptaszek, L.M., Später, D., Xu, H., Tabebordbar, M., Gorbatov, R., et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat. Biotechnol. 31 (2013), 898–907.
13. 13 Karikó, K., Buckstein, M., Ni, H., Weissman, D., Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23 (2005), 165–175.
14. 14 Karikó, K., Muramatsu, H., Welsh, F.A., Ludwig, J., Kato, H., Akira, S., Weissman, D., Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 16 (2008), 1833–1840.
15. 15 Haas, J., Engels, J.W., A convenient approach towards 2′-O-modified RNA-oligonucleotides on solid support using universal nucleosides. Nucleic Acids Symp Ser (Oxf) 52 (2008), 331–332.
16. 16 Limbach, P.A., Crain, P.F., Pomerantz, S.C., McCloskey, J.A., Structures of posttranscriptionally modified nucleosides from RNA. Biochimie 77 (1995), 135–138.
17. 17 Pardi, N., Muramatsu, H., Weissman, D., Karikó, K., In vitro transcription of long RNA containing modified nucleosides. Methods Mol. Biol. 969 (2013), 29–42.
18. 18 Kormann, M.S., Hasenpusch, G., Aneja, M.K., Nica, G., Flemmer, A.W., Herber-Jonat, S., Huppmann, M., Mays, L.E., Illenyi, M., Schams, A., et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat. Biotechnol. 29 (2011), 154–157.
19. 19 Zangi, L., Oliveira, M.S., Ye, L.Y., Ma, Q., Sultana, N., Hadas, Y., Chepurko, E., Später, D., Zhou, B., Chew, W.L., et al. Insulin-Like Growth Factor 1 Receptor-Dependent Pathway Drives Epicardial Adipose Tissue Formation After Myocardial Injury. Circulation 135 (2017), 59–72.
20. 20 Lui, K.O., Zangi, L., Silva, E.A., Bu, L., Sahara, M., Li, R.A., Mooney, D.J., Chien, K.R., Driving vascular endothelial cell fate of human multipotent Isl1+ heart progenitors with VEGF modified mRNA. Cell Res. 23 (2013), 1172–1186.
21. 21 Kondrat, J., Sultana, N., Zangi, L., Synthesis of Modified mRNA for Myocardial Delivery. Methods Mol. Biol. 1521 (2017), 127–138.
22. 22 Huang, C.L., Leblond, A.L., Turner, E.C., Kumar, A.H., Martin, K., Whelan, D., O'Sullivan, D.M., Caplice, N.M., Synthetic chemically modified mrna-based delivery of cytoprotective factor promotes early cardiomyocyte survival post-acute myocardial infarction. Mol. Pharm. 12 (2015), 991–996.
23. 23 Turnbull, I.C., Eltoukhy, A.A., Fish, K.M., Nonnenmacher, M., Ishikawa, K., Chen, J., Hajjar, R.J., Anderson, D.G., Costa, K.D., Myocardial Delivery of Lipidoid Nanoparticle Carrying modRNA Induces Rapid and Transient Expression. Mol. Ther. 24 (2016), 66–75.
24. 24 Wang, G., McCain, M.L., Yang, L., He, A., Pasqualini, F.S., Agarwal, A., Yuan, H., Jiang, D., Zhang, D., Zangi, L., et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat. Med. 20 (2014), 616–623.
25. 25 Andries, O., Mc Cafferty, S., De Smedt, S.C., Weiss, R., Sanders, N.N., Kitada, T., N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J. Control. Release 217 (2015), 337–344.
26. 26 Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B.L., Tam, Y.K., Madden, T.D., Hope, M.J., Weissman, D., Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J. Control. Release 217 (2015), 345–351.
27. 27 Lui, K.O., Zangi, L., Chien, K.R., Cardiovascular regenerative therapeutics via synthetic paracrine factor modified mRNA. Stem Cell Res. (Amst.) 13:3 Pt B (2014), 693–704.
28. 28 Chien, K.R., Zangi, L., Lui, K.O., Synthetic chemically modified mRNA (modRNA): toward a new technology platform for cardiovascular biology and medicine. Cold Spring Harb. Perspect. Med., 5, 2014, a014035.
29. 29 Boros, G., Miko, E., Muramatsu, H., Weissman, D., Emri, E., Rózsa, D., Nagy, G., Juhász, A., Juhász, I., van der Horst, G., et al. Transfection of pseudouridine-modified mRNA encoding CPD-photolyase leads to repair of DNA damage in human keratinocytes: a new approach with future therapeutic potential. J. Photochem. Photobiol. B 129 (2013), 93–99.
30. 30 Etxeberria, E., Baroja-Fernandez, E., Muñoz, F.J., Pozueta-Romero, J., Sucrose-inducible endocytosis as a mechanism for nutrient uptake in heterotrophic plant cells. Plant Cell Physiol. 46 (2005), 474–481.
31. 31 Gamm, M., Peviani, A., Honsel, A., Snel, B., Smeekens, S., Hanson, J., Increased sucrose levels mediate selective mRNA translation in Arabidopsis. BMC Plant Biol., 14, 2014, 306.
32. 32 Nicolaï, M., Roncato, M.A., Canoy, A.S., Rouquié, D., Sarda, X., Freyssinet, G., Robaglia, C., Large-scale analysis of mRNA translation states during sucrose starvation in arabidopsis cells identifies cell proliferation and chromatin structure as targets of translational control. Plant Physiol. 141 (2006), 663–673.
33. 33 Alexopoulou, L., Holt, A.C., Medzhitov, R., Flavell, R.A., Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413 (2001), 732–738.
34. 34 Koff, M.D., Plaut, K., Expression of transforming growth factor-alpha-like messenger ribonucleic acid transcripts in the bovine mammary gland. J. Dairy Sci. 78 (1995), 1903–1908.
35. 35 Hoit, B.D., Ball, N., Walsh, R.A., Invasive hemodynamics and force-frequency relationships in open- versus closed-chest mice. Am. J. Physiol. 273 (1997), H2528–H2533.
36. 36 Paulsen, S., Vetner, M., Hagerup, L.M., Relationship between heart weight and the cross sectional area of the coronary ostia. Acta Pathol. Microbiol. Scand. [A] 83 (1975), 429–432.
37. 37 Yang, L., Soonpaa, M.H., Adler, E.D., Roepke, T.K., Kattman, S.J., Kennedy, M., Henckaerts, E., Bonham, K., Abbott, G.W., Linden, R.M., et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature 453 (2008), 524–528.
38. 38 Christensen, S.D., Mikkelsen, L.F., Fels, J.J., Bodvarsdóttir, T.B., Hansen, A.K., Quality of plasma sampled by different methods for multiple blood sampling in mice. Lab. Anim. 43 (2009), 65–71.